ArticleFrontiers in pharmacology2011
Prostacyclin: an inflammatory paradox.
Article in Frontiers in pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 134 citations in OpenAlex.
- Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Trial
- Severity-associated endothelial dysfunction in post-COVID-19 patients: flow-mediated dilation and vasoactive biomarkers.Journal of thrombosis and thrombolysis · 2026Article
- In Patients Experiencing Pain and Inflammation, the Use of Non-Steroidal Anti-Inflammatory Drugs Is More Likely a Marker of the Observed Cardiovascular Risk Rather than Its Cause: A Viewpoint.Pharmacy (Basel, Switzerland) · 2026Review
- Pharmacotherapy of Kienböck Disease and the Carpal Avascular Necrosis Family: A Narrative Review with a Four-Axis Translation Framework.Medicines (Basel, Switzerland) · 2026Review
- Is there a link between non-steroidal anti-inflammatory drugs and cardiovascular risk in patients with inflammatory arthritis?Atherosclerosis plus · 2026Review
- Differential regulation of cyclic adenosine monophosphate by phosphodiesterase 3A discriminates thrombin-induced protease activated receptor 1- and 4-dependent platelet activation.Journal of thrombosis and haemostasis : JTH · 2026Article
- A selective agonist of the prostacyclin receptor alleviates microglial and astroglial neuroinflammatory responses through P38 and NLRP3.Frontiers in immunology · 2026Article
- Preparation, physicochemical properties, and immunomodulatory activity of glycoproteins from Syngnathoides biaculeatus.Natural products and bioprospecting · 2025Article
- Study on the mechanism ofAnnals of medicine · 2025Article
- The Influence of Anesthetics on the Functions of the Endothelium and Oxidative Stress: A Critical Review.Biomedicines · 2025Review
- Molecular Mechanisms of Vascular Tone in Exercising Pediatric Populations: A Comprehensive Overview on Endothelial, Antioxidative, Metabolic and Lipoprotein Signaling Molecules.International journal of molecular sciences · 2025Review
- Prostaglandins: Biological Action, Therapeutic Aspects, and Pathophysiology of Autism Spectrum Disorders.Current issues in molecular biology · 2025Review
- Acute myocardial infarction following inhaled treprostinil initiation.Respiratory medicine case reports · 2025Article
- Transcriptomics and psychotherapy: An integrative review.Brain, behavior, & immunity - health · 2024Review
- The impact of manganese on vascular endothelium.Toxicological research · 2024Review
- Signaling Paradigms of HAntioxidants (Basel, Switzerland) · 2024Review
- Transcriptional responses of brain endothelium toMicrobiology spectrum · 2024Article
- A new type of sulfation reaction:PNAS nexus · 2024Article
- Human Coronary Artery Endothelial Cell Response toMicroorganisms · 2024Article
- Single-Cell Imaging Maps Inflammatory Cell Subsets to Pulmonary Arterial Hypertension Vasculopathy.American journal of respiratory and critical care medicine · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Prostacyclin (PGI(2)) is a member of the prostaglandin family of bioactive lipids. Its best-characterized role is in the cardiovascular system, where it is released by vascular endothelial cells, serving as a potent vasodilator and inhibitor of platelet aggregation. In recent years, prostacyclin (PGI(2)) has also been shown to promote differentiation and inhibit proliferation in vascular smooth muscle cells. In addition to these well-described homeostatic roles within the cardiovascular system, prostacyclin (PGI(2)) also plays an important role as an inflammatory mediator. In this review, we focus on the contribution of prostacyclin (PGI(2)) as both a pathophysiological mediator and therapeutic agent in three major inflammatory-mediated disease processes, namely rheumatoid arthritis, where it promotes disease progression ("pro-inflammatory"), along with pulmonary vascular disease and atherosclerosis, where it inhibits disease progression ("anti-inflammatory"). The emerging role of prostacyclin (PGI(2)) in this context provides new opportunities for understanding the complex molecular basis for inflammatory-related diseases, and insights into the development of current and future anti-inflammatory treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.